Kodiak Sciences Inc Quick Ratio (KOD) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Kodiak Sciences Inc   (NASDAQ: KOD)

Kodiak Sciences Inc 's Quick Ratio

KOD's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 1.62 below Kodiak Sciences Inc average.

Within Biotechnology & Pharmaceuticals industry 83 other companies have achieved higher Quick Ratio than Kodiak Sciences Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 761 to 1267.

Explain Quick Ratio?
How much Cash & cash equivalents KOD´s has?
What are KOD´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/KOD/financial-strength
https://api.csimarket.com/api/v1/companies/KOD/fundamentals
https://api.csimarket.com/api/v1/companies/KOD/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
KOD Quick Ratio (Sep 30 2026)
Q3		 (Jun 30 2026)
Q2 		(Mar 31 2026)
Q1 		(Dec 31 2025)
Q4 		(Sep 30 2025)
Q3
Y / Y Current Liabilities Change 29.01 %
Y / Y Cash & cash equivalent Change 23.1 %
Quick Ratio MRQ 1.62
KOD's Total Ranking # 1267
Seq. Current Liabilities Change 3.73 %
Seq. Cash & cash equivalent Change -29.57 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 84
Healthcare Sector # 455
Overall Market # 1267


Quick Ratio Statistics
High Average Low
30.49 11.24 0.15
(Mar 31 2020)  




Financial Statements
Kodiak Sciences Inc 's Current Liabilities $ 55 Millions Visit KOD's Balance sheet
Kodiak Sciences Inc 's Cash & cash equivalent $ 89 Millions Visit KOD's Balance sheet
Source of KOD's Sales Visit KOD's Sales by Geography


Cumulative Kodiak Sciences Inc 's Quick Ratio

KOD's Quick Ratio for the trailling 12 Months

KOD Quick Ratio

 (Sep 30 2026)
12 Months		 (Jun 30 2026)
12 Months 		(Mar 31 2026)
12 Months 		(Dec 31 2025)
12 Months 		(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 54.13 %
Y / Y Cash & cash equivalent TTM Growth 22.94 %
Quick Ratio TTM 2.97
Total Ranking TTM # 476
Seq. Current Liabilities TTM Growth 6.55 %
Seq. Cash & cash equivalent TTM Growth 2.88 %

Quick ratio ranking by company, industry and sector >> Back to KOD Financial Strength Comparisons >> Go to Compare KOD Quick Ratio to its Competitors

On the trailing twelve months basis Due to rise in Current Liabilities in the Q3 2026 to $54.74 millions, cumulative Quick Ratio decreased to 2.97 below the Kodiak Sciences Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 139 other companies have achieved higher Quick Ratio than Kodiak Sciences Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2756 to 3720.

Explain Quick Ratio?
How much Cash & cash equivalents KOD´s has?
What are KOD´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 140
Healthcare Sector # 872
Within the Market #


trailing twelve months Quick Ratio Statistics
High Average Low
23.36 9.43 0.79
(Jun 30 2021)   (Dec 31 2018)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Biotechnology & Pharmaceuticals Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Lineage Cell Therapeutics Inc   4.42 $ 45.199  Millions$ 10.217  Millions
Ginkgo Bioworks Holdings Inc   4.33 $ 285.361  Millions$ 65.849  Millions
Fate Therapeutics Inc   4.26 $ 139.132  Millions$ 32.691  Millions
Kymera Therapeutics Inc   4.16 $ 373.374  Millions$ 89.723  Millions
Monte Rosa Therapeutics Inc   4.16 $ 577.726  Millions$ 139.022  Millions
Vir Biotechnology Inc   4.08 $ 454.635  Millions$ 111.332  Millions
Moderna Inc   3.93 $ 7,976.000  Millions$ 2,028.000  Millions
Immunocore Holdings Plc  3.93 $ 901.298  Millions$ 229.619  Millions
Alector Inc   3.92 $ 138.697  Millions$ 35.415  Millions
Dbv Technologies S a   3.89 $ 165.700  Millions$ 42.600  Millions
Regenxbio Inc   3.71 $ 250.976  Millions$ 67.684  Millions
Tenaya Therapeutics Inc   3.55 $ 66.797  Millions$ 18.804  Millions
Alpha Cognition Inc.  3.41 $ 37.802  Millions$ 11.093  Millions
Intensity Therapeutics Inc   3.29 $ 8.494  Millions$ 2.582  Millions
Vivosim Labs Inc   3.19 $ 8.564  Millions$ 2.682  Millions
Adaptive Biotechnologies Corporation  3.02 $ 298.954  Millions$ 98.967  Millions
Atyr Pharma Inc   2.96 $ 48.751  Millions$ 16.463  Millions
Precision Biosciences Inc  2.90 $ 81.846  Millions$ 28.258  Millions
Immunitybio inc   2.86 $ 334.329  Millions$ 116.795  Millions
Editas Medicine Inc   2.66 $ 190.198  Millions$ 71.582  Millions
Sutro Biopharma Inc   2.62 $ 142.177  Millions$ 54.311  Millions
Humacyte Inc   2.61 $ 64.523  Millions$ 24.761  Millions
Autolus Therapeutics Plc  2.52 $ 248.377  Millions$ 98.647  Millions
Vericel Corporation  2.44 $ 133.493  Millions$ 54.719  Millions
Adma Biologics Inc   2.25 $ 124.555  Millions$ 55.475  Millions
Cullinan Therapeutics Inc   2.20 $ 88.260  Millions$ 40.130  Millions
Exelixis Inc   2.17 $ 892.018  Millions$ 411.877  Millions
Halozyme Therapeutics Inc   2.12 $ 1,074.480  Millions$ 506.173  Millions
Relay Therapeutics Inc   2.10 $ 124.184  Millions$ 59.154  Millions
Biocryst Pharmaceuticals Inc   1.92 $ 375.334  Millions$ 195.830  Millions

Date modified: 2026-11-13T08:31:55+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.